TABLE 2.
Post-transplant demographic and clinical data
| Parameter | All (n = 441) | SCI (n = 137) | NMA (n = 304) | P | ||
|---|---|---|---|---|---|---|
| SC-B-TCMR (n = 102) | SC-TCMR (n = 15) | SC-MVI (n = 20) | ||||
| Induction immunosuppression, n (%) | ||||||
| Rabbit anti-thymocyte globulin | 302 (69) | 70 (69) | 10 (67) | 13 (65) | 209 (69) | 0.19 |
| Alemtuzumab | 90 (20) | 17 (17) | 3 (20) | 4 (20) | 66 (22) | |
| Basiliximab | 49 (11) | 15 (14) | 2 (13) | 3 (15) | 29 (9) | |
| Maintenance immunosuppression, n (%) | ||||||
| Tacrolimus/MMF | 429 (97) | 99 (97) | 13 (87) | 18 (90) | 299 (98) | 0.11 |
| Tacrolimus/azathioprine | 5 (1) | 0 (0) | 0 (0) | 0 (0) | 1 (0.5) | |
| Cyclosporine/MMF | 1 (0.5) | 1 (1) | 1 (7) | 1 (5) | 2 (1) | |
| Other | 6 (1.5) | 2 (2) | 1 (7) | 1 (5) | 2 (1) | |
| Estimated GFR (mL/min/1.73 m2), 6 mo | 56 ± 0.8 | 57 ± 2 | 49 ± 3 | 56 ± 4 | 57 ± 1 | 0.59 |
| Urine protein-to-creatinine ratio, 6 mo | 0.18 ± 0.01 | 0.20 ± 0.03 | 0.23 ± 0.05 | 0.40 ± 0.09 | 0.15 ± 0.01 | 0.004 |
| Tacrolimus trough (ng/mL), 6 mo | 7.3 ± 1.1 | 7.3 ± 0.3 | 7.0 ± 0.6 | 7.1 ± 0.5 | 7.3 ± 0.1 | 0.43 |
| DSA, no. positive/no. assessed (%) | 28/406 (7) | 10/96 (10) | 1/14 (7) | 4/20 (20) | 13/276 (5) | 0.01 |
| Class I DSA | 15/406 (4) | 5/96 (5) | 0/14 (0) | 2/20 (10) | 8/276 (3) | 0.03 |
| Class II DSA | 13/406 (3) | 5/96 (5) | 1/14 (7) | 2/20 (10) | 5/276 (2) | |
| BK viremia during year-1 post-transplant, n (%) | 118 (27) | 45 (44) | 10 (67) | 6 (30) | 57 (19) | <0.0001 |
| BK viruria during year-1 post-transplant, n (%) | 152 (35) | 50 (51) | 10 (67) | 9 (45) | 83 (28) | <0.0001 |
Comparison of post-transplant demographic and clinical data between groups. The first column shows data for the entire cohort. The P represent comparisons between the SCI group (n = 137) and the NMA group (n = 304) by Mann-Whitney U test (continuous variables) or chi-square/Fisher exact test (categorical variables). Non-normally distributed continuous variables are presented as mean ± SE.
DSA, donor-specific antibody; GFR, glomerular filtration rate; MMF, mycophenolate mofetil; NMA, no major surveillance abnormalities; SC-B-TCMR, subclinical borderline T cell-mediated rejection; SCI, subclinical inflammation; SC-MVI, subclinical microvascular injury; SC-TCMR, subclinical T cell-mediated rejection.